Clinical Scorecard: Leukoencephalopathy After Stereotactic Radiosurgery for Brain Metastases in Breast Cancer: Analysis of 1,077 Lesions from a Single Institution

At a Glance

Key Highlights

• Leukoencephalopathy is the most frequent and threatening delayed adverse radiation effect following intracranial radiotherapy.
• Stereotactic radiosurgery delivers high-dose focused radiation, improving radiological outcomes but with risk of white matter changes.
• Leukoencephalopathy grading (0–3) based on MRI FLAIR/T2 sequences distinguishes diffuse periventricular white matter changes from tumor edema.

Guideline-Based Recommendations

Diagnosis

• Use MRI with T1, T2, and FLAIR sequences for baseline and follow-up imaging every 3 months post-SRS.
• Apply volumetric analysis on T1 post-contrast images to assess tumor response (stable, progression, regression).
• Grade leukoencephalopathy from 0 (normal) to 3 (severe/diffuse) based on periventricular white matter changes on FLAIR/T2.

Management

• Consider stereotactic radiosurgery as a focused treatment modality to minimize neurocognitive impairment compared to whole-brain radiation therapy.
• Monitor patients clinically and radiologically for progression of leukoencephalopathy and tumor control.
• Secondary treatments may include repeat SRS, WBRT, or craniotomy based on tumor progression and patient status.

Monitoring & Follow-up

• Conduct clinical and MRI follow-up at baseline and every 3 months post-treatment.
• Assess Karnofsky Performance Status (KPS) and ECOG scores at follow-up to evaluate functional outcomes.
• Track changes in leukoencephalopathy grade longitudinally to identify progression.

Risks

• High-grade leukoencephalopathy (grades 2–3) is associated with cognitive dysfunction including memory, attention, and executive function deficits.
• Risk factors include radiation dose parameters and cumulative integral dose to the cranium.
• Combined WBRT and SRS may increase risk of higher-grade leukoencephalopathy compared to SRS alone.

Patient & Prescribing Data

125 patients with breast cancer brain metastases treated with stereotactic radiosurgery (1,077 lesions analyzed).

SRS provides focused high-dose radiation with improved tumor control; however, monitoring for leukoencephalopathy is critical due to potential neurocognitive adverse effects.

Clinical Best Practices

• Perform comprehensive baseline assessment including receptor status and performance scores before SRS.
• Use standardized MRI protocols and volumetric tumor analysis for accurate assessment of treatment response and white matter changes.
• Implement a simplified leukoencephalopathy grading scale to guide clinical evaluation and follow-up.
• Maintain multidisciplinary review of imaging by neurosurgeons and neuroradiologists for consistent interpretation.
• Adhere to ethical guidelines and institutional protocols for retrospective data collection and patient confidentiality.

References

• Breast cancer incidence and brain metastases statistics
• Stereotactic radiosurgery and radiotherapy modalities
• Leukoencephalopathy mechanisms and clinical impact
• Grading system for leukoencephalopathy in brain metastases